SCHEMBL1332041

SCHEMBL1332041

Cc1cccc(NC(=O)Nc2ccc(-c3ccc4c(-c5cnn(C)c5)n[nH]c4c3)cc2)c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 9/20 0.69
AXL P30530 9/20 0.61
NTRK1 P04629 4/20 0.58
FGFR1 P11362 4/20 0.56
DDR2 Q16832 1/20 0.56
CSF1R P07333 7/20 0.54
FLT1 P17948 7/20 0.54
KIT P10721 7/20 0.54
AURKB Q96GD4 7/20 0.54
AURKA O14965 5/20 0.54
ROCK2 O75116 5/20 0.54
RPS6KB1 P23443 4/20 0.54
STK3 Q13188 4/20 0.54
ROCK1 Q13464 4/20 0.54
PLK4 O00444 4/20 0.54
NTRK2 Q16620 4/20 0.54
FYN P06241 4/20 0.54
LYN P07948 4/20 0.54
SGK2 Q9HBY8 3/20 0.54
DYRK3 O43781 3/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1330486 0.95 KDR (0.62) KDRAXLNTRK1FGFR1DDR2
SCHEMBL1330301 0.90 AXL (0.60) KDRAXLNTRK1FGFR1DDR2
SCHEMBL1331695 0.90 AURKB (0.61) KDRAXLNTRK1FGFR1DDR2
SCHEMBL1331637 0.88 KDR (0.64) KDRAXLNTRK1FGFR1DDR2
SCHEMBL1330237 0.87 FGFR1 (0.70) KDRAXLNTRK1FGFR1DDR2
SCHEMBL1330136 0.86 AXL (0.62) KDRAXLFGFR1DDR2AURKB
SCHEMBL1331362 0.85 FGFR1 (0.62) KDRAXLNTRK1FGFR1DDR2
SCHEMBL1329774 0.85 FGFR1 (0.55) KDRAXLNTRK1FGFR1DDR2
SCHEMBL1331464 0.85 KDR (0.62) KDRAXLNTRK1FGFR1DDR2
SCHEMBL1330072 0.85 KDR (0.75) KDRAXLNTRK1FGFR1CSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293738-B2 Indazole inhibitors of kinase ABBOTT LABORATORIES (US) 2012-10-23 US disclosed
US-20110281868-A1 INDAZOLE INHIBITORS OF KINASE ABBOTT LABORATORIES (US) 2011-11-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281868-A1 INDAZOLE INHIBITORS OF KINASE AURKA, AURKC, AURKB KDR 11/4885AXL 399/4885NTRK1 805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.